ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Overview of attention for article published in Molecular Cancer Therapeutics, July 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Dimensions has found 28 publications that cite this research output.

Article in Cancer Medicine (May 2022)

Article in Journal of Drug Delivery Science and Technology (April 2022)

Article in Current Oncology Reports (March 2022)